Isomorphic Labs

Alphabet's AI-first drug-discovery subsidiary — the benchmark "AI + science experts" model, applying DeepMind's AlphaFold lineage to wet-lab drug design.

1. Core Product / Service

Isomorphic Labs is an AI-driven drug-discovery company spun out of google-deepmind and controlled by Alphabet. It applies deep learning — anchored on AlphaFold-class structure prediction (alphafold3) — to design drug candidates end-to-end: target identification, hit discovery, lead optimization, and preclinical validation. Its founding thesis is "digital biology": treat biology as an information-processing system that ML can model at scale, rather than using AI merely as a screening aid [local].

2. Target Users & Pain Points

Pharma partners via multi-year discovery collaborations that aim to compress early R&D timelines and raise clinical success rates — preclinical failure is the industry's dominant cost (see ai-for-science).
Pain solved: traditional drug discovery is a low-throughput, high-failure trial-and-error process; Isomorphic positions AI to move the failure point earlier and cheaper.

3. Competitive Landscape

Player	Positioning	Vs. Isomorphic
google-deepmind / alphafold3	Open structure-prediction research	Isomorphic is the commercial wet-lab arm applying that research
insilico-medicine	Generative-AI-first biotech (Pharma.AI)	Independent biotech running its own clinical programs
xtalpi	Crystal-structure prediction + AI drug discovery (China)	China-listed, physics-first CSP origin
Recursion / Schrödinger	Computational + wet-lab drug discovery	Pre-AI-era incumbents adding ML

4. Unique Observations

The "AI + science experts" playbook that Chinese AI4S teams (incl. kimi) have benchmarked against — general-model scale paired with domain experts, versus a pure-science startup building a small bespoke model [local].
Structural moat: inside Alphabet and inheriting google-deepmind's research, Isomorphic can fund long-horizon R&D with patient capital — a structural advantage over independent AI4S biotechs.
Shared model lineage: AlphaFold 3 was developed jointly by google-deepmind and Isomorphic Labs — the clearest example of the "research lab → commercial subsidiary" transfer in AI4S.

5. Financials / Funding

External rounds: Series A $600M (2025-03, led by Thrive) and Series B $2.1B (2026-05-12, led by Thrive; Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund participating) — about $2.7B raised in total; valuation undisclosed. Alphabet remains the controlling shareholder.
Partnership economics (reported): multi-year discovery collaborations with Eli Lilly and Novartis announced January 2024, each reported up to ~$3B including milestones (upfronts in the tens of millions USD). Headline figures from public reporting — verify before relying [local].
Status: pre-revenue / pre-commercial as of 2026.

6. People & Relationships

Founder / CEO: Demis Hassabis (also co-founder/CEO of google-deepmind).
Parent: Alphabet.
Partners: Eli Lilly, Novartis.
Related: alphafold3, google-deepmind, ai-for-science.